Feb 7th 2023 - Mar 21st 2023
Any price around that offering price is a safe buy... See more
also a reverse split name that closed offering, th... See more
Feb 7th 2023 - Mar 21st 2023
Remember that we are ultimately at the beginning o... See more
$TGTX makes a lot of sense to do a 300M offering here imo
The Motley Fool Stock Advisor has a track record that speaks for itself, with average recommendations that have returned over 542%*. Act now so you can start investing smarter, not harder.
*As of October 2023$79 is an introductory price for new members only. 60% discount based on the current list price of Stock Advisor of $199/year. Membership will renew annually at the then current list price.Feb 7th 2023 - Mar 21st 2023
Their management is setting up a good offering pri... See more
The pricing, the safety, the ease of usage (pill a... See more
Any price around that offering price is a safe buy, and as we seen yesterday with the slightest news this thing has the ability to run in a heart beat!
also a reverse split name that closed offering, this is the hot theme right now, $PALI $HOTH Bio is hot this month.
$PALI Yummy dips offering closed so no risk of dilution in the near time
$PALI offering closed moving up
$PALI AH run up following offering closing!
$PALI closing offering AH, easy +30%
$PALI great opportunity imo offering closes AH too
That's a great thing so u fud spreaders calling it a offering are full of crap,stop your bs
$PALI excited for next week looking forward to the offering closing and any new news.
$12 offering.. easy $4+
Remember that we are ultimately at the beginning of commercialization and quite possible the safest spot to be with the current facts on our superior Briumvi treatment and best pricing for market share penetration.
$TGTX makes a lot of sense to do a 300M offering here imo
What stuck out was the combined value proposition: efficacy, safety, convenience, marketability, pricing, etc.
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,
$TGTX FDA approval for Billion dollar MS drug — great things in store 2023 $DRMA just officially dropped offering, makes me feel company has something good up it’s sleeve.
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,
Amazing positive news from the TGTX 20221229 conference call, FDA approved, 🚨🔥🚨 Ublituximab Briumvi: 1) No need for additional funds, no offering, no need for capital raise, because 220 million in cash reserves expected to last until mid 2024.
Their management is setting up a good offering price, which is alright
The pricing, the safety, the ease of usage (pill and no MRI's) and the efficacy/performance.
Add to that their ca$h position and the likelihood of a offering in the next few days makes this an easy short.
It is the perfect timing set to have the attention of Wall Street and to be in the spotlights the whole week long, offering free champagne to everyone at CTAD.
